Background: Cochrane is a recognized source of quality evidence that informs health-related decisions. As an organization, it represents a global network of diverse stakeholders. Cochrane's key organizational values include diversity and inclusion, to enable wide participation and promote access. However, the diversity of Cochrane review authorship has not been well summarized. Objective: The aim of this study was to examine the distribution of country, region, language, and gender diversity in the authorship of Cochrane reviews. Methods: We retrieved all published articles from the Cochrane Library (until November 6, 2023)-a web crawling technique that extracted pre-specified data fields, including publication date, review type, and author affiliations. We used E-utility calls to capture the data for non-Cochrane systematic reviews. We determined the country and region of affiliations and the gender of the first, corresponding, and last authors for Cochrane reviews, as well as the country and region of affiliations and the gender of the first authors for non-Cochrane reviews. Trends in geographical and gender diversity over time were evaluated using logistic regression. Fisher's exact test was used for comparisons. The diversity of first authors between Cochrane and non-Cochrane reviews was explored through visual presentation, Pearson's product-moment correlation, and the Granger Causality Test. We used R for data collection and analysis. Results: A total of 22681 citations were retrieved. The United Kingdom had the highest first-author representation (33.2%), followed by Australia (11.6%) and the United States (7.0%). We observed an increase in the proportion of first authors from non-English speaking countries, from 16.7% in 1996 to 42.8% in 2023. Female first authorship increased steadily, from 15.0% in 1996 to 55.6% in 2023. The proportion of first authors from lower-and-middle-income countries (LMICs) was highest in 2012 at 23.2%. Since then, it has decreased to 18.4% in 2023. Similarly, the proportion of last authors from LMICs decreased over time (25.0% in 1996 vs. 16.2% in 2023). Among review groups, Sexually Transmitted Infections and Consumers and Communication were the most and least diverse groups with 68.1% and 1.6% of first authors from LMICs, respectively. In terms of gender diversity, Fertility Regulation had the highest percentage of female first authors (72.1%). Urology (28.1%) had the lowest percentage of female first authors. In 2023, over half of the non-Cochrane reviews had first authors from non-English-speaking countries (n=14,589, 56.9%), 50.8% (n=13,014) had first authors from LMICs, and 42.3% (n=10,841) had female first authors. The Pearson's product-moment correlations between Cochrane and non-Cochrane reviews' trends were 0.265 (P=0.450) for LMICs, 0.823 (P<0.001) for non-English speaking, 0.634 (P<0.001) Spanish-speaking, and 0.829 (P<0.001) for female first authorship. Conclusion: Overall, this study found positive trends, with an increase in first authorship by individuals who were female and from non-English speaking countries. However, the representation of first authors from non-high-income countries decreased. Future research could further explore these trends, identifying potential barriers influencing access and participation of individuals and groups and assessing strategies that help promote diversity and inclusion.

AS-M, EV, AB-P, EN, AS, LEM, and SC-dO are members of the steering group of the Early Career Professionals Network in Cochrane. ET, VAW, LM, and PT are members of the Health Equity Thematic Group in Cochrane. VAW declares funding from CIHR-PHAC Applied Public Health Chair.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All datasets and codes of workflows used in this study are publically available (OSF: https://osf.io/fv5ys, GitHub: https://github.com/choxos/cochraneauthors).

https://osf.io/fv5ys